EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Long-term treatment patterns and outcomes in IgG4-related disease – a retrospective single-center cohort study focusing on rituximab

Ariane Hammitzsch, Noemi Ferraro, Quirin Bachmann, Uwe Heemann, Philipp Moog

Rheumatology International · 2026

DOI: 10.1007/s00296-025-06065-1 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Rheumatology International, 2026. Verfasst von Ariane Hammitzsch und 4 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology, Department of Nephrology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich, Ismaninger Strass…. Hauptthemen laut MEDLINE: Rituximab, Immunoglobulin G4-Related Disease, Immunosuppressive Agents, Antirheumatic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IgG4-related disease (IgG4-RD) is a rare immune-mediated, fibroinflammatory disease with heterogenous presentations and no standardized treatment recommendations. This study investigates long-term efficacy and safety of current therapeutic strategies with a focus on rituximab. A retrospective analysis was conducted on 24 patients diagnosed with IgG4-RD at a German tertiary center (2010–2020) using the 2020 revised comprehensive diagnostic criteria. Patients were recruited from Rheumatology and Nephrology. Data included organ involvement, laboratory results, histology, treatments, relapses, therapy-related damage, and comorbidities. The cohort included 12 males and 12 females, median age at diagnosis 53 (95%CI 37.0; 61.0) years. Males had more affected organs (2.4 vs. 1.6; p = 0.036) and higher IgG4 levels (>5× upper limit: 33.3% vs. 16.7%; p = 0.036). Immunosuppressive therapy was initiated in 87.5% of patients, with glucocorticoids (GC) universally included. Rituximab was administered to 71.4%, mainly as a 4 x 375 mg/m² regimen (77.3%), with a median follow-up post first rituximab of 51.0 months (95%CI 27.0; 63.0). Adverse events were not more frequent with rituximab compared to other regimens. At last visit, 47.6% were off immunosuppressives and 38.1% remained on GC. Active organ involvement declined, though 16.7% showed organ damage progression. Relapses were frequent (81.0%), but less common upon rituximab initiation (26.7%). This representative IgG4-RD cohort demonstrates that long-term treatment with rituximab as maintenance therapy is generally effective and safe regardless of therapeutic regimen. Despite this glucocorticoid use remains high, highlighting the need for guidelines to standardize the use of glucocorticoids and DMARDs like rituximab in both induction and maintenance therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabImmunoglobulin G4-Related DiseaseImmunosuppressive AgentsAntirheumatic AgentsImmunologic FactorsHumansMaleFemaleRetrospective StudiesMiddle AgedTreatment OutcomeAgedAdultGlucocorticoidsRecurrence

Stichwörter der Autor:innen

B cell depleting therapyCohort studyIgG4-RDObservational studyRelapseRetrospective studyRituximabSafety aspectsTherapeutic outcome

Substanzen

RituximabImmunosuppressive AgentsGlucocorticoidsAntirheumatic AgentsImmunologic Factors

Autor:innen und Institutionen

  • Rheumatology, Department of Nephrology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany. Ariane.Hammitzsch@mri.tum.de.
  • Rheumatology, Department of Nephrology, TUM School of Medicine and Health, TUM University Hospital, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.

Förderung

  • Technische Universität München

Zitieren

APA

Hammitzsch, A., Ferraro, N., Bachmann, Q., Heemann, U., & Moog, P. (2026). Long-term treatment patterns and outcomes in IgG4-related disease – a retrospective single-center cohort study focusing on rituximab. Rheumatology International. https://doi.org/10.1007/s00296-025-06065-1

Vancouver

Hammitzsch A, Ferraro N, Bachmann Q, Heemann U, Moog P. Long-term treatment patterns and outcomes in IgG4-related disease – a retrospective single-center cohort study focusing on rituximab. Rheumatology International. 2026. doi:10.1007/s00296-025-06065-1

BibTeX
@article{Hammitzsch2026,
  author = {Hammitzsch, Ariane and Ferraro, Noemi and Bachmann, Quirin and Heemann, Uwe and Moog, Philipp},
  title = {Long-term treatment patterns and outcomes in IgG4-related disease – a retrospective single-center cohort study focusing on rituximab},
  journal = {Rheumatology International},
  year = {2026},
  doi = {10.1007/s00296-025-06065-1}
}
Kostenlos starten →